-
SAB Biotherapeutics President And CEO Eddie J. Sullivan, PhD, Featured On COVID-19 Panel At BIO Digital 2020
SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully…
-
This Cow’s Antibodies Could Be The Newest Weapon Against COVID-19
By Mitch Leslie Jun. 5, 2020 , 4:35 PM Science’s COVID-19 reporting is supported by the Pulitzer Center. The latest recruits in the fight against…
-
SAB Biotherapeutics Confirms Neutralizing Antibodies To SARS-CoV-2 And Begins Clinical Manufacturing Of Novel COVID-19 Therapeutic Candidate
SAB-185 is a human polyclonal antibody therapeutic that potently neutralizes live SARS-CoV-2 at titers 4X higher than convalescent plasma. Data suggests…
-
Researchers Use Cows To Develop Antibody Treatment
Scientists at SAb Biotherapeutics are planning to start studies this summer on coronavirus treatments created by using antibodies derived from cows with…
-
I Am BIO | “Herd” Immunity Podcast
Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel…
-
Convalescent Serum Lines Up As First-Choice Treatment For Coronavirus
May 1, 2020 | Cormac Sheridan Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of…
-
Jodi’s Journal: The Little Biotech Company That Could Beat COVID-19
By : Jodi Schwan, April 26, 2020 I deliberately put an attention-grabbing headline on this column, but it’s one I plan to back up with what I’m about to…
-
Behind SAB’s Rapid Response To COVID-19
BY SANDI WONG, ASSISTANT EDITOR | APR 24, 2020 | 6:48 PM CDT SAB had already been working with the U.S. Department of Defense to prepare its human…
-
SAB Biotherapeutics Advances Therapeutic For COVID-19 In Partnership With Department Of Defense And BARDA
SAB’s novel approach generates targeted human antibodies without the need for human donors; on-track to have therapeutic candidate ready by summer 2020…
-
HHS Facilitates Development Of Immunotherapies For COVID-19 Patients
April 13, 2020 In the race to identify and provide safe, effective treatments for hospitalized patients with COVID-19 , the U.S. Department of Health and…
-
CSL Behring And SAB Biotherapeutics Join Forces To Deliver New Potential COVID-19 Therapeutic
April 08, 2020 at 8 a.m. ET COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2,…
-
BARDA, Department Of Defense, And SAb Biotherapeutics To Partner To Develop A Novel COVID-19 Therapeutic
A therapeutic to treat novel coronavirus disease 2019 (COVID-19) is moving forward in development through a partnership between BARDA, the Department of…